Abstract
As the end of the twentieth century approaches new methods are needed for the treatment and control of tuberculosis. Vaccination needs to be rethought, and BCG either improved or replaced. Chemotherapy is no longer enough to meet the needs of impoverished countries, non-compliant patients, and increasingly drug-resistant organisms. The next major step forward should logically come from immunology. Following the clear differentiation of two pathways of cellular immune response to mycobacterial challenge, and the recent description of two functional types of helper T cells, ideas of what controls them have allowed the logical development of a potential new vaccine and a new immunotherapy. These are based on a killed environmental organism, Mycobacterium vaccae NCTC 11659. With this simple preparation together with chemotherapy we may be armed as never before to face the inevitable challenge that tuberculosis will present to the twenty first century. Parallels recognised between cell death in tuberculosis and infection with the human immunodeficiency virus open the possibility that the progress made in immunotherapy in tuberculosis might be applicable to HIV. If this proves the case then we may also have control over the latest, and worst, risk factor for tuberculosis at the time we need it most.
MeSH Terms
BCG Vaccine
Drug Resistance, Microbial
Humans
Immunotherapy
Tuberculosis/drug therapy,prevention & control,therapy
Vaccination
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Stanford J L
University College London Medical School.
Grange J M
References (26)
26 references, click to expand
-
Immunotherapy for drug-resistant tuberculosis.
Lancet. 1992 Nov 28;340(8831):1360-1
PMID: 1360082
-
The mystery of the mycobacterial 'persistor'.
Tuber Lung Dis. 1992 Oct;73(5):249-51
PMID: 1493231
-
Theoretical and methodological aspects of BCG vaccine from the discovery of Calmette and Guérin to molecular biology. A review.
Tuber Lung Dis. 1992 Oct;73(5):252-61
PMID: 1493232
-
Tuberculosis: commentary on a reemergent killer.
Science. 1992 Aug 21;257(5073):1055-64
PMID: 1509256
-
Koch's phenomenon: can it be corrected?
Tubercle. 1991 Dec;72(4):241-9
PMID: 1811354
-
Treatment of tuberculosis by private general practitioners in India.
Tubercle. 1991 Dec;72(4):284-90
PMID: 1811360
-
Cytokines and the Koch phenomenon.
Tubercle. 1991 Mar;72(1):13-20
PMID: 1882441
-
The Koch phenomenon and delayed hypersensitivity: 1891-1991.
Tubercle. 1991 Mar;72(1):7-11
PMID: 1882447
-
Tuberculosis and the acquired immune deficiency syndrome.
J Appl Bacteriol. 1991 Jul;71(1):19-30
PMID: 1894579
-
Improving on BCG.
APMIS. 1991 Feb;99(2):103-13
PMID: 2001276
-
Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis.
Vaccine. 1990 Dec;8(6):525-30
PMID: 2087873
-
Improved immunotherapy for pulmonary tuberculosis with Mycobacterium vaccae.
Tubercle. 1990 Dec;71(4):259-66
PMID: 2267679
-
A pilot study of three potential vaccines for leprosy in Bombay.
Int J Lepr Other Mycobact Dis. 1989 Mar;57(1):33-7
PMID: 2659699
-
Vaccination and skin test studies on the children of leprosy patients.
Int J Lepr Other Mycobact Dis. 1989 Mar;57(1):38-44
PMID: 2659700
-
Stress proteins are immune targets in leprosy and tuberculosis.
Proc Natl Acad Sci U S A. 1988 Jun;85(12):4267-70
PMID: 3132709
-
The secreted antigens of Mycobacterium tuberculosis and their relationship to those recognized by the available antibodies.
J Gen Microbiol. 1988 Feb;134(2):531-8
PMID: 3139828
-
Suppressor determinants of mycobacteria and their potential relevance to leprosy.
Lepr Rev. 1986 Jun;57(2):147-57
PMID: 3747706
-
The meaning and structure of species as applied to mycobacteria.
Tubercle. 1974 Jun;55(2):143-52
PMID: 4220078
-
BCG vaccination of children against leprosy: nine-year findings of the controlled WHO trial in Burma.
Bull World Health Organ. 1974;51(1):93-9
PMID: 4281729
-
Trial of BCG vaccines in south India for tuberculosis prevention.
Indian J Med Res. 1979 Sep;70:349-63
PMID: 535944
-
B.C.G. vaccination of children against leprosy: first results of a trial in Uganda.
Br Med J. 1966 Jan 1;1(5478):7-14
PMID: 5900912
-
Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis.
Am Rev Respir Dis. 1966 Oct;94(4):553-68
PMID: 5924215
-
How environmental mycobacteria may predetermine the protective efficacy of BCG.
Tubercle. 1981 Mar;62(1):55-62
PMID: 7268920
-
A TH1-->TH2 switch is a critical step in the etiology of HIV infection.
Immunol Today. 1993 Mar;14(3):107-11
PMID: 8096699
-
Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced cytokine expression and elevated beta 2-microglobulin in HIV-1-associated tuberculosis.
J Infect Dis. 1993 Jan;167(1):43-8
PMID: 8418182
-
Chemoprophylaxis for tuberculosis.
Respir Med. 1993 Feb;87(2):81-3
PMID: 8497689